Humanwell Healthcare (600079.SH) has obtained drug registration certificates for fentanyl citrate lozenges and ketorolac acetic acid injections.

Humanwell Healthcare (600079.SH) announced that its subsidiaries Yichang Renfu Pharmaceutical Co., Ltd. ("Yichang Renfu", in which the company holds 80% equity) and Wuhan Renfulicon Pharmaceutical Co., Ltd. ("Renfulicon", in which the company and its wholly-owned subsidiaries hold 80% equity, with a future repurchase agreement based on the capital increase agreement granting the company 100% ownership) have recently received approval from the National Medical Products Administration for the issuance of Drug Registration Certificates for the buccal tablets of fentanyl citrate and the injection of triptorelin acetate. The buccal tablets of fentanyl citrate are used to treat breakthrough pain in cancer patients. Currently, there are no approved buccal tablets of fentanyl citrate for sale in the domestic market, nor are there any related products approved for import. Triptorelin acetate injections are used in assisted reproductive technology to prevent premature ovulation in patients undergoing controlled ovarian stimulation. The approval of these drugs signifies that the subsidiaries are now eligible to sell these drugs in the domestic market, enriching the company's product line and bringing positive impacts through their sales.